Akero Therapeutics, Inc. - COMMON STOCK (AKRO) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
AKRO
Shares outstanding
79,376,583
Price per share
$54.65
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
91,447,333
Total reported value
$4,342,160,695
% of total 13F portfolios
0.01%
Share change
-751,248
Value change
-$45,117,857
Number of holders
260
Price from insider filings
$54.65
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GENERAL ATLANTIC, L.P. 8.4% $244,469,709 6,796,489 General Atlantic, L.P. 31 Mar 2025
JANUS HENDERSON GROUP PLC 7.9% -6.7% $298,188,881 -$21,757,757 6,280,305 -6.8% JANUS HENDERSON GROUP PLC 30 Sep 2025
RTW INVESTMENTS, LP 7.3% -25% $286,911,096 -$48,191,258 5,873,308 -14% RTW Investments, LP 30 Jun 2025
Deep Track Capital, LP 5.5% $208,910,680 4,400,000 Deep Track Capital, LP 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 5.3% +25% $201,878,360 +$39,974,124 4,251,861 +25% Wellington Management Group LLP 30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/ 4.8% $180,902,408 3,810,076 T. Rowe Price Associates, Inc. 30 Sep 2025

As of 30 Sep 2025, 260 institutional investors reported holding 91,447,333 shares of Akero Therapeutics, Inc. - COMMON STOCK (AKRO). This represents 115% of the company’s total 79,376,583 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 7.9% 6,280,305 -6.8% 0.14% $298,242,505
GENERAL ATLANTIC, L.P. 7.2% 5,733,989 0% 8.2% $272,249,798
BlackRock, Inc. 7.2% 5,702,634 -1.3% 0% $270,761,064
RTW INVESTMENTS, LP 6.9% 5,477,561 0% 3.2% $260,074,596
VANGUARD GROUP INC 5.7% 4,526,920 -0.06% 0% $214,938,161
WELLINGTON MANAGEMENT GROUP LLP 5.4% 4,251,861 +25% 0.04% $201,878,361
Deep Track Capital, LP 5% 4,000,978 +31% 5.3% $189,966,435
Avoro Capital Advisors LLC 5% 3,955,555 +13% 2.4% $187,809,751
PRICE T ROWE ASSOCIATES INC /MD/ 4.8% 3,809,859 -16% 0.02% $180,893,000
STATE STREET CORP 4.3% 3,414,306 +24% 0.01% $162,111,249
Bellevue Group AG 3% 2,389,314 +20% 2.4% $113,444,628
ALKEON CAPITAL MANAGEMENT LLC 2.3% 1,850,934 0% 0.4% $87,882,346
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,785,586 +3.7% 0.01% $84,792,838
ALLIANCEBERNSTEIN L.P. 2.1% 1,689,629 +10% 0.03% $80,223,585
Point72 Asset Management, L.P. 2.1% 1,663,339 -39% 0.17% $78,975,351
BANK OF AMERICA CORP /DE/ 1.6% 1,297,438 -1.7% 0% $61,602,356
MARSHALL WACE, LLP 1.5% 1,217,044 -14% 0.06% $57,785,250
Logos Global Management LP 1.5% 1,200,000 0% 5.6% $56,976,000
PERCEPTIVE ADVISORS LLC 1.4% 1,135,766 +24% 1.6% $53,926,170
FMR LLC 1.4% 1,079,657 +16% 0% $51,262,104
Polar Capital Holdings Plc 1.3% 1,058,776 0.24% $50,270,684
Holocene Advisors, LP 1.3% 1,055,186 -1.9% 0.12% $50,100,231
Pictet Asset Management Holding SA 1.2% 926,441 -6.1% 0.04% $43,997,202
GOLDMAN SACHS GROUP INC 1.1% 855,766 +12% 0.01% $40,631,770
DIMENSIONAL FUND ADVISORS LP 1% 810,568 +41% 0.01% $38,486,653

Institutional Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$33,205,306 $54.65 0
2025 Q3 91,447,333 $4,342,160,695 -$45,117,857 $47.48 260
2025 Q2 92,131,681 $4,916,497,064 +$352,115,033 $53.36 253
2025 Q1 86,154,634 $3,503,843,455 +$531,433,651 $40.48 238
2024 Q4 74,174,925 $2,063,407,386 -$8,506,912 $27.82 188
2024 Q3 73,002,069 $2,094,264,841 +$38,303,106 $28.69 170
2024 Q2 71,815,872 $1,684,847,663 -$32,487,986 $23.46 152
2024 Q1 73,077,343 $1,845,721,808 +$381,089,994 $25.26 172
2023 Q4 67,306 $1,603,085 +$601,988 $23.68 2
2023 Q3 56,752,909 $2,870,500,101 +$62,927,207 $50.58 177
2023 Q2 56,232,003 $2,625,040,126 +$390,002,421 $46.69 154
2023 Q1 47,991,522 $1,835,983,880 -$63,182,586 $38.26 153
2022 Q4 48,529,463 $2,659,071,482 +$142,847,557 $54.80 155
2022 Q3 46,362,085 $1,578,582,246 +$488,238,971 $34.05 138
2022 Q2 34,708,081 $328,127,739 -$12,017,913 $9.45 102
2022 Q1 34,963,281 $496,153,069 -$4,320,403 $14.19 95
2021 Q4 35,197,329 $744,225,550 +$3,822,622 $21.15 92
2021 Q3 27,992,670 $625,965,377 +$6,661,443 $22.35 102
2021 Q2 25,736,505 $638,356,429 -$130,813,908 $24.81 94
2021 Q1 31,496,381 $913,319,371 +$20,567,393 $29.01 108
2020 Q4 30,812,124 $812,970,792 +$45,256,723 $25.80 92
2020 Q3 28,987,374 $892,449,434 +$220,243,052 $30.79 102
2020 Q2 21,827,155 $543,916,299 -$5,678,739 $24.92 75
2020 Q1 21,718,693 $460,421,796 +$62,765,569 $21.20 65
2019 Q4 19,000,379 $421,605,474 +$18,157,474 $22.19 57
2019 Q3 12,742,598 $288,264,741 +$54,821,798 $22.75 54
2019 Q2 10,674,595 $204,526,000 +$204,525,923 $19.15 48